This is a BRK.B holding. It's turned neg on the year. Nearing the 0% Fib level. Time to buy?
BMY
branchjames61
Sep 19, 2021
Praveen Chawla
Sep 19, 2021
I don't understand technical analysis, but this is a decent buy. Morningstar indicated fair value at $68. Its a wide moat company with good prospects. Dividend of 3.3%.
Currently, I favour Merck over BMY but own both.
manciata
Nov 22, 2021
Buffett or surrogate reduced position.
I'm selling this morning. It's been a discouraging hold for me, and I've now lost patience. Got to be better opportunities elsewhere. (I would like to believe.)
yvazifda
May 22, 2022
Nah i like it, seems like decent businesss, with reasonably resilient drug pipeline and its not like its selling for outrageous prices. should it drop another 10-20% then it will be more attractive than getting a $9 pizza for $4 at dominos hahhahaa ahahaha
Merck pipeline strong. I rate merck as slightly better than pfizer which kinda is old clunky and one of those slow stodgy old things
